Executive summary: Evaluating drug company copay assistance programs Manufacturer copay assistance programs represent a meaningful component of commercial investment for many life sciences companies and can play an important role in patient affordability and brand access. Because these programs also often involve operational complexity and rapidly changing market dynamics, manufacturers need a structured basis for evaluating whether program design remains well matched to current conditions.
